PhaseBio Pharmaceuticals ROIC

ROIC of PHAS for past 10 years: annual, quarterly and twelve month trailing (TTM) including ROIC growth rates and interactive chart. Return on invested capital (ROIC) is a calculation used to assess a company's efficiency at allocating the capital under its control to profitable investments. Calculated as Net Operating Profit After Tax or EBIT*(1-tax rate) divided by average invested capital. Invested capital is calculated as equity plus long-term and short-term debt minus cash and short-term investments. ROIC is often compared to the Weighted average cost of capital (WACC). If it's above it, it is said the company is creating value, if it's below it's destroying it. A company with after tax operating profit of $10 million and invested capital of $50 million will have a ROIC of 20%.


Highlights and Quick Summary

  • Annual ROIC for 2020 was 0.0% (a -100.0% decrease from previous year)
  • Annual ROIC for 2019 was -1022.02% (a -Infinity% decrease from previous year)
  • Annual ROIC for 2018 was 0.0% (a NaN% decrease from previous year)
  • Twelve month ROIC ending September 29, 2021 was 0.0% (a NaN% decrease compared to previous quarter)
  • Twelve month trailing ROIC decreased by NaN% year-over-year
Trailing ROIC for the last four month:
29 Sep '21 29 Jun '21 30 Mar '21 30 Dec '20
0.0% 0.0% 0.0% 0.0%
Visit stockrow.com/PHAS for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical ROIC of PhaseBio Pharmaceuticals

Most recent ROICof PHAS including historical data for past 10 years.

Interactive Chart of ROIC of PhaseBio Pharmaceuticals

PhaseBio Pharmaceuticals ROIC for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 0.0%
2019 -1022.02%
2018 0.0%
2017 0.0%
2016 0.0%

Business Profile of PhaseBio Pharmaceuticals

Sector: Healthcare
Industry: Biotechnology
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania.